http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 17 Aug 2026 07:43:56 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Rigel+Pharmaceuticals+%28RIGL%29+PT+Raised+to+%2449+at+Piper+Sandler/26934911.html Piper Sandler analyst Allison Bratzel raised the price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $49.00 (from $40.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Rigel+Pharmaceuticals+%28RIGL%29+PT+Raised+to+%2449+at+Piper+Sandler/26934911.html Mon, 17 Aug 2026 07:43:56 -0400 RIGL http://www.streetinsider.com/Analyst+PT+Change/Rigel+Pharmaceuticals+%28RIGL%29+PT+Raised+to+%2485+at+H.C.+Wainwright/26934555.html H.C. Wainwright analyst Joseph Pantginis raised the price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $85.00 (from $57.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Rigel+Pharmaceuticals+%28RIGL%29+PT+Raised+to+%2485+at+H.C.+Wainwright/26934555.html Mon, 17 Aug 2026 06:45:59 -0400 RIGL http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++RIGEL+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926375.html si-local-file:///var/storage/secattach/20260814/26926375.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++RIGEL+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926375.html Fri, 14 Aug 2026 10:25:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++RIGEL+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926375.html si-local-file:///var/storage/secattach/20260814/26926375.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++RIGEL+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926375.html Fri, 14 Aug 2026 10:25:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++RIGEL+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26917416.html si-local-file:///var/storage/secattach/20260813/26917416.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++RIGEL+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26917416.html Thu, 13 Aug 2026 09:00:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++RIGEL+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26917416.html si-local-file:///var/storage/secattach/20260813/26917416.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++RIGEL+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26917416.html Thu, 13 Aug 2026 09:00:00 -0400 O.00187291 RIGL http://www.streetinsider.com/Corporate+News/Rigel+launches+breast+cancer+drug+Veppanu+at+%2429%2C400+per+month/26916900.html <p>Rigel Pharmaceuticals (NASDAQ: RIGL) announced that Veppanu (vepdegestrant) is now available by prescription in the United States for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy.</p><p>The drug, priced at $29,400 per 30-day supply, is available through specialty distributors and specialty pharmacies in the United States and Puerto Rico. The recommended dose is 200 mg taken orally once daily.</p><p>The FDA approved Veppanu in May 2026. The agency describes it as the first approved drug in the PROTAC (PROteolysis TArgeting Chimera) class, which works by degrading disease-causing proteins http://www.streetinsider.com/Corporate+News/Rigel+launches+breast+cancer+drug+Veppanu+at+%2429%2C400+per+month/26916900.html Thu, 13 Aug 2026 08:05:40 -0400 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html <div class="xn-content"> <p class="prntac"><i>VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, </i><i>ESR1-mutated mBC</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU^TM (vepdegestrant) is now available by prescription in <location value="LC/us" idsrc="xmltag.org" >the United States</location> for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (<i>ESR1</i>)-mutated advanced or metastatic breast cancer (mBC), as detected http://www.streetinsider.com/Press+Releases/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html Thu, 13 Aug 2026 08:05:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html <div class="xn-content"> <p class="prntac"><i>VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, </i><i>ESR1-mutated mBC</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU^TM (vepdegestrant) is now available by prescription in <location value="LC/us" idsrc="xmltag.org" >the United States</location> for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (<i>ESR1</i>)-mutated advanced or metastatic breast cancer (mBC), as detected http://www.streetinsider.com/Press+Releases/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html Thu, 13 Aug 2026 08:05:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html <div class="xn-content"> <p class="prntac"><i>VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, </i><i>ESR1-mutated mBC</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU^TM (vepdegestrant) is now available by prescription in <location value="LC/us" idsrc="xmltag.org" >the United States</location> for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (<i>ESR1</i>)-mutated advanced or metastatic breast cancer (mBC), as detected http://www.streetinsider.com/Press+Releases/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html Thu, 13 Aug 2026 08:05:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html <div class="xn-content"> <p class="prntac"><i>VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, </i><i>ESR1-mutated mBC</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU^TM (vepdegestrant) is now available by prescription in <location value="LC/us" idsrc="xmltag.org" >the United States</location> for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (<i>ESR1</i>)-mutated advanced or metastatic breast cancer (mBC), as detected http://www.streetinsider.com/Press+Releases/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html Thu, 13 Aug 2026 08:05:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/PRNewswire/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html <div class="xn-content"> <p class="prntac"><i>VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, </i><i>ESR1-mutated mBC</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU^TM (vepdegestrant) is now available by prescription in <location value="LC/us" idsrc="xmltag.org" >the United States</location> for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (<i>ESR1</i>)-mutated advanced or metastatic breast cancer (mBC), as detected http://www.streetinsider.com/PRNewswire/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html Thu, 13 Aug 2026 08:05:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/PRNewswire/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html <div class="xn-content"> <p class="prntac"><i>VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, </i><i>ESR1-mutated mBC</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU^TM (vepdegestrant) is now available by prescription in <location value="LC/us" idsrc="xmltag.org" >the United States</location> for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (<i>ESR1</i>)-mutated advanced or metastatic breast cancer (mBC), as detected http://www.streetinsider.com/PRNewswire/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html Thu, 13 Aug 2026 08:05:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/PRNewswire/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html <div class="xn-content"> <p class="prntac"><i>VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, </i><i>ESR1-mutated mBC</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU^TM (vepdegestrant) is now available by prescription in <location value="LC/us" idsrc="xmltag.org" >the United States</location> for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (<i>ESR1</i>)-mutated advanced or metastatic breast cancer (mBC), as detected http://www.streetinsider.com/PRNewswire/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html Thu, 13 Aug 2026 08:05:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/PRNewswire/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html <div class="xn-content"> <p class="prntac"><i>VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, </i><i>ESR1-mutated mBC</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU^TM (vepdegestrant) is now available by prescription in <location value="LC/us" idsrc="xmltag.org" >the United States</location> for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (<i>ESR1</i>)-mutated advanced or metastatic breast cancer (mBC), as detected http://www.streetinsider.com/PRNewswire/Rigel+Announces+Availability+of+VEPPANU%E2%84%A2+%28vepdegestrant%29+for+Patients+with+ER%2BHER2-%2C+ESR1-Mutated+Advanced+or+Metastatic+Breast+Cancer/26916891.html Thu, 13 Aug 2026 08:05:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++RIGEL+PHARMACEUTICALS++++++++++++++++/26867246.html si-local-file:///var/storage/secattach/20260804/26867246.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++RIGEL+PHARMACEUTICALS++++++++++++++++/26867246.html Tue, 04 Aug 2026 16:37:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++RIGEL+PHARMACEUTICALS++++++++++++++++/26867246.html si-local-file:///var/storage/secattach/20260804/26867246.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++RIGEL+PHARMACEUTICALS++++++++++++++++/26867246.html Tue, 04 Aug 2026 16:37:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Aug+04/26866354.html si-local-file:///var/storage/secattach/20260804/26866354.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Aug+04/26866354.html Tue, 04 Aug 2026 16:10:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Aug+04/26866354.html si-local-file:///var/storage/secattach/20260804/26866354.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Aug+04/26866354.html Tue, 04 Aug 2026 16:10:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+30/26866207.html si-local-file:///var/storage/secattach/20260804/26866207.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+30/26866207.html Tue, 04 Aug 2026 16:07:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+30/26866207.html si-local-file:///var/storage/secattach/20260804/26866207.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+30/26866207.html Tue, 04 Aug 2026 16:07:00 -0400 O.00187291 RIGL http://www.streetinsider.com/Earnings/Rigel+Pharmaceuticals+%28RIGL%29+Tops+Q2+EPS+by+67c%3B+Offers+Guidance/26866110.html <p>Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 EPS of $0.88, $0.67 better than the analyst estimate of $0.21. Revenue for the quarter came in at $78.7 million versus the consensus estimate of $54.94 million.</p><p><strong>GUIDANCE:</strong></p><p>Rigel Pharmaceuticals sees FY2026 revenue of $285-295 million, versus the consensus of $278.9 million.</p><p>For earnings history and earnings-related data on Rigel Pharmaceuticals (RIGL) <a href="http://www.streetinsider.com/ec_earnings.php?q=RIGL">click here</a>.</p> http://www.streetinsider.com/Earnings/Rigel+Pharmaceuticals+%28RIGL%29+Tops+Q2+EPS+by+67c%3B+Offers+Guidance/26866110.html Tue, 04 Aug 2026 16:05:53 -0400 RIGL http://www.streetinsider.com/Guidance/Rigel+Pharmaceuticals+%28RIGL%29+Tops+Q2+EPS+by+67c%3B+Offers+Guidance/26866110.html <p>Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 EPS of $0.88, $0.67 better than the analyst estimate of $0.21. Revenue for the quarter came in at $78.7 million versus the consensus estimate of $54.94 million.</p><p><strong>GUIDANCE:</strong></p><p>Rigel Pharmaceuticals sees FY2026 revenue of $285-295 million, versus the consensus of $278.9 million.</p><p>For earnings history and earnings-related data on Rigel Pharmaceuticals (RIGL) <a href="http://www.streetinsider.com/ec_earnings.php?q=RIGL">click here</a>.</p> http://www.streetinsider.com/Guidance/Rigel+Pharmaceuticals+%28RIGL%29+Tops+Q2+EPS+by+67c%3B+Offers+Guidance/26866110.html Tue, 04 Aug 2026 16:05:53 -0400 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Reports+Second+Quarter+2026+Financial+Results/26865850.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter 2026 total revenues of <money>$78.7 million</money>, including net product sales of <money>$67.0 million</money> and contract revenues from collaborations of <money>$11.7 million</money>, and net income of <money>$17.3 million</money></i></li><li><i>Expanded commercial portfolio with the in-license of VEPPANU™</i> <i>(vepdegestrant), with <location value="LC/us" idsrc="xmltag.org" >U.S</location>. commercial availability expected in mid-August</i></li><li><i>Advanced R289 development program; Phase 1b study in patients with lower-risk MDS remains on track to complete enrollment in the dose expansion portion and select the recommended Phase 2 dose in the second half of 2026</i></li><li><i>Updated 2026 Outlook: Total revenues of approximately <money>$285</money> to <money>$295 million</money>, which includes net product sales, excluding VEPPANU, http://www.streetinsider.com/Press+Releases/Rigel+Reports+Second+Quarter+2026+Financial+Results/26865850.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.22847412 A.50213980 A.50216726 O.00187291 O.03960636 O.13786904 O.20026344 O.21612337 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Reports+Second+Quarter+2026+Financial+Results/26865850.html <div class="xn-content"> <ul type="disc"><li><i>Second quarter 2026 total revenues of <money>$78.7 million</money>, including net product sales of <money>$67.0 million</money> and contract revenues from collaborations of <money>$11.7 million</money>, and net income of <money>$17.3 million</money></i></li><li><i>Expanded commercial portfolio with the in-license of VEPPANU™</i> <i>(vepdegestrant), with <location value="LC/us" idsrc="xmltag.org" >U.S</location>. commercial availability expected in mid-August</i></li><li><i>Advanced R289 development program; Phase 1b study in patients with lower-risk MDS remains on track to complete enrollment in the dose expansion portion and select the recommended Phase 2 dose in the second half of 2026</i></li><li><i>Updated 2026 Outlook: Total revenues of approximately <money>$285</money> to <money>$295 million</money>, which includes net product sales, excluding VEPPANU, http://www.streetinsider.com/Press+Releases/Rigel+Reports+Second+Quarter+2026+Financial+Results/26865850.html Tue, 04 Aug 2026 16:01:00 -0400 A.06822034 A.22847412 A.50213980 A.50216726 O.00187291 O.03960636 O.13786904 O.20026344 O.21612337 RIGL